8-K: Jaguar Health Reports 16% Revenue Increase in Q2 2024, Plans Gelclair Launch

Jaguar Health announced a 16% increase in Q2 2024 revenue compared to Q1 2024, driven by prescription and non-prescription product sales, and is planning an October 2024 launch for Gelclair.

Summary

• Jaguar Health reported a combined net revenue of approximately $2.72 million for Q2 2024, which is a 16% increase compared to Q1 2024 revenue of $2.35 million.
• The Q2 2024 revenue also represents a 2% increase compared to Q2 2023 revenue of $2.67 million.
• Mytesi revenue was $2.64 million in Q2 2024, a 15% increase from Q1 2024 and a 1% increase from Q2 2023.
• Mytesi prescription volume increased by 5.2% in Q2 2024 compared to Q1 2024, but decreased by 0.4% compared to Q2 2023.
• The company plans to commercially launch Gelclair in October 2024.
• Jaguar is analyzing data from the OnTarget trial of crofelemer for cancer therapy-related diarrhea and will explore potential FDA approval pathways for breast and lung cancer.
• The company is supporting investigator-initiated studies of crofelemer for rare diseases, with results expected by the end of 2024 and throughout 2025.
• The import permit for crofelemer for a study in Abu Dhabi for pediatric patients with MVID or SBS has been granted.
• The net loss attributable to common shareholders decreased by $2.6 million, from $12.1 million in Q2 2023 to $9.5 million in Q2 2024.
• Non-GAAP recurring EBITDA was a net loss of $8.8 million for Q2 2024, compared to a net loss of $7.7 million for Q2 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and reduced losses, but the worsening non-GAAP recurring EBITDA and the risks associated with drug development temper the overall sentiment.

Positives

• The company experienced a 16% increase in total revenue in Q2 2024 compared to Q1 2024.
• Mytesi revenue saw a 15% increase in Q2 2024 compared to Q1 2024.
• The company is set to launch Gelclair in October 2024, expanding its product portfolio.
• Jaguar is actively exploring new indications for crofelemer, specifically in breast and lung cancer.
• The company has secured an import permit for a study in Abu Dhabi, expanding its research reach.
• The net loss attributable to common shareholders decreased by 28% year-over-year, indicating improved financial performance.
• Research and Development expenses decreased by $0.6 million year-over-year, showing cost management.

Negatives

• Mytesi prescription volume decreased by 0.4% in Q2 2024 compared to Q2 2023.
• Non-GAAP recurring EBITDA was a net loss of $8.8 million for Q2 2024, compared to a net loss of $7.7 million for Q2 2023, indicating a worsening of this metric.
• Revenues for non-prescription Neonorm products were minimal for both Q2 2024 and Q2 2023.

Risks

• The company's future success depends on the successful commercialization of Gelclair.
• The company's ability to obtain FDA approval for crofelemer in breast and lung cancer is uncertain.
• The company's ongoing research and development efforts may not yield positive results.
• The company's financial performance is still showing a net loss, and the non-GAAP recurring EBITDA has worsened year-over-year.
• The company's reliance on a closed network of specialty pharmacies for Mytesi sales could impact revenue if buying patterns change.

Future Outlook

The company anticipates the commercial launch of Gelclair in October 2024, and is exploring potential FDA approval pathways for crofelemer in breast and lung cancer. Results from investigator-initiated studies of crofelemer for rare diseases are expected by the end of 2024 and throughout 2025.

Management Comments

• Lisa Conte, Jaguar's president and CEO, stated that the company's paramount near-term activities are the planned October 2024 commercial launch of Gelclair, progressing the rare disease development business, and the ongoing analysis of the OnTarget trial data.
• Management is collaborating with clinical and scientific advisors to evaluate the significance of the results identified in patients with breast and lung cancer from the OnTarget trial.

Industry Context

The announcement highlights Jaguar Health's focus on developing treatments for gastrointestinal distress and rare diseases, aligning with the growing demand for specialized therapies in these areas. The company's focus on plant-based medicines also taps into the increasing interest in natural and sustainable healthcare solutions.

Comparison to Industry Standards

• While Jaguar Health's revenue growth is positive, it is important to compare it to other pharmaceutical companies in the same space, such as those focused on gastrointestinal or rare disease treatments.
• Companies like Salix Pharmaceuticals (acquired by Bausch Health) and Shire (now part of Takeda) have established benchmarks in the gastrointestinal space, and Jaguar's revenue and growth rates should be compared against these.
• For rare disease treatments, companies like BioMarin Pharmaceutical and Alexion Pharmaceuticals (now part of AstraZeneca) are key comparators, and Jaguar's progress in this area should be evaluated against their development timelines and commercial success.
• The company's focus on plant-based medicines is a differentiator, but its success will depend on its ability to demonstrate clinical efficacy and commercial viability compared to traditional pharmaceutical approaches.

Stakeholder Impact

• Shareholders may view the revenue growth and reduced losses positively.
• Employees may be impacted by the company's cost management efforts.
• Patients may benefit from the potential approval of crofelemer for new indications.
• Customers may benefit from the launch of Gelclair.
• Suppliers may see increased demand for raw materials as the company expands its product offerings.

Next Steps

• The company will complete the analysis of the OnTarget trial data.
• The company will engage in discussions with the FDA regarding a potential approval pathway for crofelemer in breast and lung cancer.
• The company will launch Gelclair commercially in October 2024.
• The company will continue to support investigator-initiated studies of crofelemer for rare diseases.
• The company will continue to monitor and manage its financial performance.

Key Dates

Keywords

Jaguar Health, crofelemer, Mytesi, Gelclair, OnTarget trial, cancer therapy-related diarrhea, CTD, rare diseases, microvillus inclusion disease, MVID, short bowel syndrome, SBS, revenue, financial results, prescription products, non-prescription products